1239460-75-3

Usage

Uses

Used in Pharmaceutical Synthesis:
5-bromo-8-(trifluoromethyl)quinoline is used as an intermediate in the synthesis of pharmaceutical drugs. Its unique structure allows for the development of new drugs with potential therapeutic benefits.
Used in Agrochemicals:
5-bromo-8-(trifluoromethyl)quinoline is also utilized in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used in Materials Science:
5-bromo-8-(trifluoromethyl)quinoline is used as a fluorescent material in materials science due to its fluorescence properties. This makes it suitable for applications in fluorescence imaging and other related fields.
Used in Antimicrobial Applications:
5-bromo-8-(trifluoromethyl)quinoline has been studied for its potential antimicrobial properties, making it a candidate for use in the development of new antimicrobial agents to combat resistant bacteria.
Used in Antiviral Applications:
Research into the antiviral properties of 5-bromo-8-(trifluoromethyl)quinoline is ongoing, with the potential for it to be used in the development of antiviral drugs to treat various viral infections.

Upstream product

• 887144-94-7 Togni's reagent II 
• 4964-71-0 5-bromoquinoline 
• 703-91-3 5-bromo-2-trifluoromethylphenylamine 
• 56-81-5 glycerol 

Relevant academic research and scientific papers

Transition metal-free direct C–H trifluoromethyltion of (hetero)arenes with Togni's reagent

A new transition-metal-free direct C–H trifluoromethylation reaction of (hetero)arenes with Togni's reagent was developed. This transformation proceeded smoothly under mild conditions and exhibited good tolerance of many synthetically relevant functional groups. It provided an alternative approach for the synthesis of trifluoromethylated (hetero)arenes.

Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration

The SAR of a series of brain penetrant, trisubstituted thiophene based JNK inhibitors with improved pharmacokinetic properties is described. These compounds were designed based on information derived from metabolite identification studies which led to compounds such as 42 with lower clearance, greater brain exposure and longer half life compared to earlier analogs.

INHIBITORS OF JUN N-TERMINAL KINASE

The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.